RecruitingNot ApplicableNCT07146776

Treatment of Intrabony Defects With Injectable Platelet-Rich Fibrin and Xenogenic Grafts

Evaluation of the Effect of Injectable Platelet-Rich Fibrin in the Treatment of Periodontal Intrabony Defects With Xenogenic Grafts: a Randomized Controlled Clinical Trial

Sponsor

Saglik Bilimleri Universitesi

Enrollment

16 participants

Start Date

Jul 12, 2025

Study Type

INTERVENTIONAL

Conditions

Periodontal Diseases Periodontitis Intrabony Periodontal Defect Periodontal Defect Periodontal Bone Loss

Summary

The use of injectable platelet-rich fibrin (i-PRF) in both surgical and non-surgical dental treatments has become increasingly widespread. Hard tissue grafts can produce "sticky bone," and bone gain can have a positive effect on intrabony defects frequently seen in periodontal disease, compared to grafts alone. This study aims to clinically and radiographically evaluate the effectiveness of using bovine-derived xenogenic bone grafts in combination with i-PRF and bovine-derived xenogeneic bone grafts alone in patients with intrabony defects and stage III periodontitis.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria5

Male and female patients aged 18-65 years
Patients with Stage III Periodontitis according to the AAP-EFP 2017 Periodontal Disease Classification
PPD≥5 mm (if persistent 6 weeks after initial periodontal treatment)
Intrabony defects in the interproximal region with 2 or 3 walls and a depth of at least ≥3 mm
Non-smokers (those who smoke up to 10 per day may be included)

Exclusion Criteria12

Patients under 18 years of age or older than 65 years of age
Patients unable to consent
Systemic diseases that could affect the success of surgery, such as uncontrolled diabetes
Single-walled intrabony defects
Those who have taken antibiotics, anti-inflammatory or immunosuppressive drugs, or birth control pills within the three months prior to the study
Those who have received active periodontal treatment within the last six months and periodontal surgery within the last year
Smoking more than 10 cigarettes per day
Pregnancy or breastfeeding
Those taking medications that affect the gums (e.g., calcium channel blockers, phenytoin or cyclosporine)
Teeth with furcation defects
Those undergoing active orthodontic treatment
Those who are allergic to the biomaterials used in the study or prescribed medications

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREopen flap debridement with I-prf and xenogeneic graft

During the surgical phase of treatment, patients will undergo open flap debridement surgery. Infiltrative local anesthesia will first be administered to the involved teeth. The gingiva will be incised within the gingival sulcus using a scalpel, and a full-thickness flap will be carefully elevated with a periosteal elevator. Granulation tissue and dental calculus will be completely removed using Gracey curettes (American Eagle, USA) and an ultrasonic scaler. Subsequently, a xenogeneic bone graft mixed with injectable platelet-rich fibrin (i-PRF) will be applied. The flap will then be sutured using 4-0 polypropylene sutures.

PROCEDUREopen flap debridement with saline and xenogenic graft

During the surgical phase of treatment, patients will undergo open flap debridement surgery. Infiltrative local anesthesia will first be administered to the involved teeth. The gingiva will be incised within the gingival sulcus using a scalpel, and a full-thickness flap will be carefully elevated with a periosteal elevator. Granulation tissue and dental calculus will be thoroughly removed using Gracey curettes (American Eagle, USA) and an ultrasonic scaler. A xenogeneic bone graft mixed with physiological saline will then be applied. Finally, the flap will be sutured using 4-0 polypropylene sutures.